AU2020250832A1 - Osimertinib for use in the treatment of non-small cell lung cancer - Google Patents
Osimertinib for use in the treatment of non-small cell lung cancer Download PDFInfo
- Publication number
- AU2020250832A1 AU2020250832A1 AU2020250832A AU2020250832A AU2020250832A1 AU 2020250832 A1 AU2020250832 A1 AU 2020250832A1 AU 2020250832 A AU2020250832 A AU 2020250832A AU 2020250832 A AU2020250832 A AU 2020250832A AU 2020250832 A1 AU2020250832 A1 AU 2020250832A1
- Authority
- AU
- Australia
- Prior art keywords
- egfr
- egfr tki
- tki
- osimertinib
- generation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023233122A AU2023233122B2 (en) | 2019-03-29 | 2023-09-21 | Osimertinib for use in the treatment of non-small cell lung cancer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825867P | 2019-03-29 | 2019-03-29 | |
| US62/825,867 | 2019-03-29 | ||
| PCT/EP2020/058729 WO2020201097A1 (en) | 2019-03-29 | 2020-03-27 | Osimertinib for use in the treatment of non-small cell lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023233122A Division AU2023233122B2 (en) | 2019-03-29 | 2023-09-21 | Osimertinib for use in the treatment of non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020250832A1 true AU2020250832A1 (en) | 2021-11-11 |
Family
ID=70224330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020250832A Abandoned AU2020250832A1 (en) | 2019-03-29 | 2020-03-27 | Osimertinib for use in the treatment of non-small cell lung cancer |
| AU2023233122A Active AU2023233122B2 (en) | 2019-03-29 | 2023-09-21 | Osimertinib for use in the treatment of non-small cell lung cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023233122A Active AU2023233122B2 (en) | 2019-03-29 | 2023-09-21 | Osimertinib for use in the treatment of non-small cell lung cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12465608B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946346A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022526159A (cg-RX-API-DMAC7.html) |
| KR (2) | KR102992349B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113645976A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020250832A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3133766A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202192552A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA55508A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011810A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020201097A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259147A4 (en) * | 2020-12-11 | 2024-10-23 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| CN117098537A (zh) * | 2020-12-11 | 2023-11-21 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| US20240309363A1 (en) * | 2021-01-12 | 2024-09-19 | Georgia Tech Research Corporation | Combination therapeutics for treatment of proliferative disorders |
| CN119768173A (zh) * | 2022-09-01 | 2025-04-04 | 齐鲁制药有限公司 | 一种egfr激酶抑制剂的用途 |
| TW202515577A (zh) * | 2023-06-27 | 2025-04-16 | 日商大鵬藥品工業股份有限公司 | 患有具有egfr畸變的非小細胞肺癌之個體的治療方法 |
| CN121177212B (zh) * | 2025-11-25 | 2026-03-03 | 中南大学湘雅二医院 | 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| WO2006068826A2 (en) | 2004-12-21 | 2006-06-29 | Smithkline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| WO2007067506A2 (en) | 2005-12-05 | 2007-06-14 | Smithkline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| EP2040546A4 (en) | 2006-06-22 | 2009-12-23 | Merck & Co Inc | tyrosine kinase inhibitor |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| CA2663599A1 (en) * | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2012501654A (ja) | 2008-09-05 | 2012-01-26 | アビラ セラピューティクス, インコーポレイテッド | 不可逆的インヒビターの設計のためのアルゴリズム |
| WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| CA2778265A1 (en) | 2009-11-02 | 2011-05-05 | Abbott Laboratories | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| ES2622138T3 (es) | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| LT2964638T (lt) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| AU2014324478A1 (en) * | 2013-09-30 | 2016-05-05 | Amgen, Inc. | Nucleic acid biomarker and use thereof |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN107530434A (zh) * | 2015-04-23 | 2018-01-02 | 免疫医疗有限公司 | 非小细胞肺癌egfr突变阳性的联合疗法 |
| WO2017200016A1 (ja) | 2016-05-17 | 2017-11-23 | 公益財団法人がん研究会 | Egfr-tki耐性を獲得した肺癌の治療薬 |
| WO2018102827A1 (en) | 2016-12-04 | 2018-06-07 | Expression Pathology, Inc. | Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| MA51823A (fr) | 2018-02-12 | 2021-05-19 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
-
2020
- 2020-03-27 JP JP2021557206A patent/JP2022526159A/ja active Pending
- 2020-03-27 MX MX2021011810A patent/MX2021011810A/es unknown
- 2020-03-27 AU AU2020250832A patent/AU2020250832A1/en not_active Abandoned
- 2020-03-27 MA MA055508A patent/MA55508A/fr unknown
- 2020-03-27 EP EP20717570.4A patent/EP3946346A1/en active Pending
- 2020-03-27 KR KR1020217035042A patent/KR102992349B1/ko active Active
- 2020-03-27 EA EA202192552A patent/EA202192552A1/ru unknown
- 2020-03-27 US US17/593,923 patent/US12465608B2/en active Active
- 2020-03-27 CN CN202080025201.0A patent/CN113645976A/zh active Pending
- 2020-03-27 WO PCT/EP2020/058729 patent/WO2020201097A1/en not_active Ceased
- 2020-03-27 CA CA3133766A patent/CA3133766A1/en active Pending
- 2020-03-27 KR KR1020267022344A patent/KR20260115768A/ko active Pending
-
2023
- 2023-09-21 AU AU2023233122A patent/AU2023233122B2/en active Active
-
2025
- 2025-05-27 JP JP2025087802A patent/JP2025131642A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3946346A1 (en) | 2022-02-09 |
| AU2023233122B2 (en) | 2025-07-24 |
| CN113645976A (zh) | 2021-11-12 |
| JP2022526159A (ja) | 2022-05-23 |
| KR102992349B1 (ko) | 2026-07-15 |
| US12465608B2 (en) | 2025-11-11 |
| CA3133766A1 (en) | 2020-10-08 |
| US20220175783A1 (en) | 2022-06-09 |
| KR20260115768A (ko) | 2026-07-24 |
| AU2023233122A1 (en) | 2023-10-05 |
| JP2025131642A (ja) | 2025-09-09 |
| EA202192552A1 (ru) | 2021-12-17 |
| WO2020201097A1 (en) | 2020-10-08 |
| MX2021011810A (es) | 2021-10-26 |
| KR20210144844A (ko) | 2021-11-30 |
| MA55508A (fr) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12465608B2 (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| Cappuzzo et al. | Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus | |
| US20240423978A1 (en) | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | |
| CN104717961A (zh) | 使用含脂质体伊立替康的组合疗法治疗胰腺癌的方法 | |
| JP7712955B2 (ja) | 癌の治療のための投薬レジメン | |
| US20240173293A1 (en) | Treatment of Breast Cancer with Amcenestrant and Palbociclib | |
| EP4431154A2 (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| Bennouna et al. | Phase II study evaluating the mechanisms of resistance on tumor tissue and liquid biopsy in patients with EGFR-mutated non-pretreated advanced lung cancer receiving osimertinib until and beyond radiologic progression: the MELROSE trial | |
| TW202329970A (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| EP4181927A1 (en) | Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent | |
| US20250186393A1 (en) | Treatment of breast cancer with amcenestrant | |
| EA052374B1 (ru) | Осимертиниб для применения в лечении немелкоклеточного рака легкого | |
| WO2023183354A1 (en) | Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer | |
| WO2023141087A1 (en) | Combination therapy with a mutant idh inhibitor | |
| HK40124174A (en) | Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer | |
| CN117580572A (zh) | 用安森司坦和帕博西尼治疗乳腺癌 | |
| FLT3-ITD–mutant | A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia | |
| AU2019255410A1 (en) | Nazartinib for use in the treatment of CNS metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |